Fda lifts clinical hold on fulcrum therapeutics' ftx-6058 for sickle cell disease

Cambridge, mass., aug. 22, 2023 (globe newswire) -- fulcrum therapeutics, inc.® (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the u.s. food and drug administration (fda) has lifted the clinical hold on the investigational new drug (ind) application for ftx-6058 for the potential treatment of sickle-cell disease (scd).
FULC Ratings Summary
FULC Quant Ranking